Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
India Services Sector Rebounds in January as New Business Gains Momentum: HSBC PMI Shows Growth 
US-India Trade Bombshell: Tariffs Slashed to 18% — Rupee Soars, Sensex Explodes 
Australia’s Corporate Regulator Urges Pension Funds to Boost Technology Investment as Industry Grows 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
